Ï A.N. åîïìïëïãåßôáé...

Boy Ôï áóôåßï óôçí äéêéÜ ìïõ éóôïñßá åßíáé üôé áëëéþò öáíôáæüìïõí ðùò èá áíôéäñïýóá áí ðïôÝ ìïõ ôý÷áéíå êÜôé ôÝôïéï êáé ôåëéêÜ áëëéþò áíôÝäñáóá üôáí ôï Ýìáèá.

ÐÜíôá ðßóôåõá ðþò áí ìÜèáéíá üôé åß÷á ìïëõíèåß ìå ôïí éü, èá óôáìáôïýóá áêüìç êáé íá æù ðáñüëï ðïõ äåí èá Þìïõí åðßóéìá êëéíéêÜ íåêñüò.
Ðßóôåõá üôé èá óôáìáôïýóá íá ÷áìïãåëÜù, íá âãáßíù, íá ïíåéñåýïìáé, áêüìç êáé íá äïõëåýù.

Êáé íá ðïõ ôåëéêÜ ìïõ Ýôõ÷å.
ÌÝñá ìå ôç ìÝñá üìùò áíáêáëýðôù üôé åßìáé ðéï äõíáôüò áðü üóï íüìéæá üôé ðÜíôá Þìïõí.
¼÷é ìüíï äåí âÜæù ôç æùÞ ìïõ óôï ðåñéèþñéï, áëëÜ áíôéèÝôùò Ý÷ù ìéá åðéèõìßá íá ôá âéþóù üëá ðéï Ýíôïíá.
¹ôáí ç êáêéÜ ç þñá, áëëÜ ïðùò ëÝåé êáé ç ëÝîç, "Þôáí..."
Äåí èá ôçò åðéôñÝøù íá "åßíáé..."

Äåí êáôçãïñþ êáíÝíáí ãéá áõôü.
Äåí ìå ðßåóå êáíåßò íá êÜíù êÜôé ðáñÜ ôçí èÝëçóç ìïõ.
¼õôå ìå åíäéáöÝñåé íá âñù ôïí õðáßôéï ðïõ ìïõ ìåôÝäùóå ôïí éü.
¼ðïéïò êáé áí åßíáé, áò æåé ðëÝïí ìå ôéò äéêÝò ôïõ ôýøåéò.
Åãþ åõôõ÷þò, ìÝóá óôçí áôõ÷ßá ìïõ, ôï Ýìáèá áñêåôÜ íùñßò êáé èá ìðïñÝóù íá ôï áíôéìåôùðßóù óáí êÜôé ðïõ èá Ý÷ù ðÜíôá ìÝóá ìïõ áëëÜ ðïõ ðïôÝ äåí èá áöÞóù íá âãåé ðñïò ôá Ýîù.

ÁðëÜ Ý÷ù êïõñáóôåß ëßãï.
Ìå Ý÷åé êïõñÜóåé íá ðëçãþíù ôïõò áíèñþðïõò ãýñù ìïõ ãéá ôéò åðéëïãÝò ìïõ.
Áíèñþðïõò ðïõ îÝñù üôé ìå áãáðïýí.

Äåí öôáßù üìùò åãþ ãéá üëá áõôÜ.
ÈÝëù ìüíï íá ðéóôåýù üôé áõôïß ðïõ ìå áãáðïýí ðñáãìáôéêÜ èá ðáñáìåßíïõí äßðëá ìïõ.
¹ ôïõëÜ÷éóôïí èá ðñïóðáèÞóïõí íá ðáñáìåßíïõí äßðëá ìïõ.
Ãéáôß îÝñù ðùò ëåéôïõñãåß ï öüâïò ìÝóá óôïõò áíèñþðïõò êÜðïéåò öïñÝò.
Åîáöáíßæåé üëá ôá ùñáßá êáé åóôéÜæåé óôï êáêü ðïõ Ýñ÷åôáé, ÷ùñßò íá êÜíåé óôÜóç ðïõèåíÜ óôï åíäéÜìåóï.
¸íá êüêêéíï öùò ðïõ áíáâïóâÞíåé óõíå÷þò êáé ðñïåéäïðïéåß.
¸ôóé èá åßíáé êáé ç æùÞ ìïõ áðü åäþ êáé ðÝñá.
¸íá êüêêéíï öùôÜêé ðïõ èá áíÜâåé êáé èá óâÞíåé.
Ðüóï èá Þèåëá íá åßíáé ìüíéìá ðñÜóéíï.
¼ðùò ôüôå ðñéí ôï ìÜèù.

ÊáììéÜ öïñÜ üôáí êëåßíù ôá ìÜôéá ìïõ, íïìßæù ðùò ôï íéþèù íá êõëÜåé ìÝóá ìïõ.
Óå üëåò ôéò öëÝâåò ôïõ êïñìéïý ìïõ.
Óôï êåöÜëé êáé óôá ÷Ýñéá ìïõ.
¢ñáãå èá ìðïñÝóåé ðïôÝ íá öýãåé áõôÞ ç óêÝøç áðï ôï ìõáëü ìïõ;

Ìéá óêÝøç ðïõ Ýñ÷åôáé ðÜëé êáé ðÜëé.
ÌÝóá óå üëá ðïõ óõëëïãßæïìáé ìÝóá óôçí çìÝñá, ðñïóôÝèçêå áêüìç Ýíá ðñÜãìá.
Ìå ôç äéáöïñÜ üôé ôï óõãêåêñéìÝíï åðáíáëáìâÜíåôáé óõíå÷þò.
Êáé åêåß ðïõ íïìßæù ðùò âñÞêá êÜôé Üëëï íá áó÷ïëïýìáé, åðáíÝñ÷åôáé êáé ìåôÜ ðÜëé öåýãåé áëëÜ ðÜíôá âñßóêåé ôï äñüìï ðßóù óôï ìõáëü ìïõ.
Óáí åíá óêõëß ðïõ ôï áöÞíåéò åëåýèåñï áëëÜ ðÜíôá îÝñåé íá ãõñßóåé åêåß ðïõ åßíáé ôï óðßôé ôïõ.
¸ôóé êáé áõôü.

Åãþ ðëÝïí Ý÷ù ãßíåé ôï óðßôé ôïõ êáé áõôü ðïôÝ äåí èá ÷áèåß óôç äéáäñïìÞ üóï åßìáé æùíôáíüò.
Êáé åãþ áõôü ôï óðßôé äåí Ý÷ù óêïðü íá ôï åãêáôáëåßøù...

Á.Í.




... 'Aëëåò éóôïñßåò ...



Lancet

Ðñüóöáôåò äçìïóéåýóåéò óôï ðåñéïäéêü The Lancet HIV

Optimised second-line regimens in the public health approach

Globally, most people receive antiretroviral therapy (ART) in programmes that follow the WHO-recommended public health approach, using a small number of standard regimens and simplified monitoring.1 A single standard regimen—dolutegravir (an integrase strand transfer inhibitor [INSTI]) with tenofovir disoproxil fumarate and lamivudine (both nucleoside reverse transcriptase inhibitors, [NRTIs])—is currently taken by the large majority of people on ART in these programmes, including those on second-line therapy (following previous failure of a non-NRTI regimen).

Prioritising HIV drug resistance testing according to risk

Tenofovir–lamivudine–dolutegravir (TLD) is recommended as an initial treatment regimen and a preferred optimised regimen for people living with HIV without a history of previous viral non-suppression, referred to as TLD in first-line therapy (TLD-1). For people living with HIV with persistent viral non-suppression, TLD largely replaced protease inhibitor-based regimens following efavirenz-based initial regimens, referred to as TLD in second-line therapy (TLD-2), as it is at least as effective, better tolerated, and more affordable.

Ending paediatric AIDS: time to close implementation gaps

WHO's global health sector strategies on HIV, conceived to guide the health sector in implementing strategically focused responses to achieve the goals of ending AIDS by 2030, target a reduction in the number of children aged 0–14 years newly infected with HIV from 150 000 in 2022 to 20 000 in 2025 and 15 000 in 2030.1 To track progress toward these targets, accurate estimations of the number of annual infections in children in each country is crucial. However, in many low-income and middle-income countries, where the burden of paediatric HIV is the highest, children are not systematically tested for HIV in programmes for the prevention of vertical transmission (PVT).

About us

Óôï hivaids.gr, öéëïîåíïýìå áöéëïêåñäþò ôï "Ðñüãñáììá Óõíåñãáóßáò" ÌïíÜäùí Ëïéìþîåùí ãéá ôçí áíÜðôõîç äéáäéêôõáêÞò ôñÜðåæáò êëéíéêþí ðáñáìÝôñùí. Ôï Ðñüãñáììá äçìéïõñãÞèçêå áðü Ýíáí ãéáôñü åéäéêü óôçí HIV ëïßìùîç ìå ôç óõììåôï÷Þ ôùí ÌïíÜäùí: Ðåñéóóüôåñá

% Áíáðçñßá êáé HIV

ÍÝïò êáíïíéóìüò

Åíéáßïò Ðßíáêáò Ðñïóäéïñéóìïý Ðïóïóôïý Áíáðçñßáò

Çìåñïëüãéï

@ Äéáýãåéá

ÄéáýãåéáÄé@ýãåéá

äéáöÜíåéá óôï êñÜôïò

ÄéáäéêôõáêÝò áíáñôÞóåéò äéïéêçôéêþí áðïöÜóåùí ãéá ôï HIV/AIDS

¸ñåõíá

Óáò Ý÷åé óðÜóåé ðïôÝ ôï ðñïöõëáêôéêü êáôÜ ôç äéÜñêåéá ìéáò åñùôéêÞò åðáöÞò;
Íáé
¼÷é
Äåí ÷ñçóéìïðïéþ

Åðéêïéíùíßá

Newsletter

Áíáêïéíþóåéò

×ñÞóéìåò ðëçñïöïñßåò